Cargando…
The Paradigm Change of IL-33 in Vascular Biology
In this review, we focus on the actual understanding of the role of IL-33 in vascular biology in the context of the historical development since the description of IL-33 as a member of IL-1 superfamily and the ligand for ST2 receptor in 2005. We summarize recent data on the biology, structure and si...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707059/ https://www.ncbi.nlm.nih.gov/pubmed/34948083 http://dx.doi.org/10.3390/ijms222413288 |
_version_ | 1784622344142061568 |
---|---|
author | Demyanets, Svitlana Stojkovic, Stefan Huber, Kurt Wojta, Johann |
author_facet | Demyanets, Svitlana Stojkovic, Stefan Huber, Kurt Wojta, Johann |
author_sort | Demyanets, Svitlana |
collection | PubMed |
description | In this review, we focus on the actual understanding of the role of IL-33 in vascular biology in the context of the historical development since the description of IL-33 as a member of IL-1 superfamily and the ligand for ST2 receptor in 2005. We summarize recent data on the biology, structure and signaling of this dual-function factor with both nuclear and extracellular cytokine properties. We describe cellular sources of IL-33, particularly within vascular wall, changes in its expression in different cardio-vascular conditions and mechanisms of IL-33 release. Additionally, we summarize the regulators of IL-33 expression as well as the effects of IL-33 itself in cells of the vasculature and in monocytes/macrophages in vitro combined with the consequences of IL-33 modulation in models of vascular diseases in vivo. Described in murine atherosclerosis models as well as in macrophages as an atheroprotective cytokine, extracellular IL-33 induces proinflammatory, prothrombotic and proangiogenic activation of human endothelial cells, which are processes known to be involved in the development and progression of atherosclerosis. We, therefore, discuss that IL-33 can possess both protective and harmful effects in experimental models of vascular pathologies depending on experimental conditions, type and dose of administration or method of modulation. |
format | Online Article Text |
id | pubmed-8707059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87070592021-12-25 The Paradigm Change of IL-33 in Vascular Biology Demyanets, Svitlana Stojkovic, Stefan Huber, Kurt Wojta, Johann Int J Mol Sci Review In this review, we focus on the actual understanding of the role of IL-33 in vascular biology in the context of the historical development since the description of IL-33 as a member of IL-1 superfamily and the ligand for ST2 receptor in 2005. We summarize recent data on the biology, structure and signaling of this dual-function factor with both nuclear and extracellular cytokine properties. We describe cellular sources of IL-33, particularly within vascular wall, changes in its expression in different cardio-vascular conditions and mechanisms of IL-33 release. Additionally, we summarize the regulators of IL-33 expression as well as the effects of IL-33 itself in cells of the vasculature and in monocytes/macrophages in vitro combined with the consequences of IL-33 modulation in models of vascular diseases in vivo. Described in murine atherosclerosis models as well as in macrophages as an atheroprotective cytokine, extracellular IL-33 induces proinflammatory, prothrombotic and proangiogenic activation of human endothelial cells, which are processes known to be involved in the development and progression of atherosclerosis. We, therefore, discuss that IL-33 can possess both protective and harmful effects in experimental models of vascular pathologies depending on experimental conditions, type and dose of administration or method of modulation. MDPI 2021-12-10 /pmc/articles/PMC8707059/ /pubmed/34948083 http://dx.doi.org/10.3390/ijms222413288 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Demyanets, Svitlana Stojkovic, Stefan Huber, Kurt Wojta, Johann The Paradigm Change of IL-33 in Vascular Biology |
title | The Paradigm Change of IL-33 in Vascular Biology |
title_full | The Paradigm Change of IL-33 in Vascular Biology |
title_fullStr | The Paradigm Change of IL-33 in Vascular Biology |
title_full_unstemmed | The Paradigm Change of IL-33 in Vascular Biology |
title_short | The Paradigm Change of IL-33 in Vascular Biology |
title_sort | paradigm change of il-33 in vascular biology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707059/ https://www.ncbi.nlm.nih.gov/pubmed/34948083 http://dx.doi.org/10.3390/ijms222413288 |
work_keys_str_mv | AT demyanetssvitlana theparadigmchangeofil33invascularbiology AT stojkovicstefan theparadigmchangeofil33invascularbiology AT huberkurt theparadigmchangeofil33invascularbiology AT wojtajohann theparadigmchangeofil33invascularbiology AT demyanetssvitlana paradigmchangeofil33invascularbiology AT stojkovicstefan paradigmchangeofil33invascularbiology AT huberkurt paradigmchangeofil33invascularbiology AT wojtajohann paradigmchangeofil33invascularbiology |